News - MedTech & Diagnostics
The private health illusion: Australians pay for premium care but get yesterday’s medical technology

Australians with private health insurance believe they have premium access to medical technology – but do they? In this Health Industry Hub podcast, Sarah Najdek, Managing Director ANZ at Johnson & Johnson MedTech, and Dr Emily Kotschet, Electrophysiologist at the Victorian Heart Hospital, unpack new national research that exposes the widening gap between perception and reality in the private healthcare system.
The findings are hard to ignore: 86% of Australians assume private healthcare provides equal, if not greater, access to the latest medical technology. Yet the reality tells a different story.
“A lot of technology lags in the private system a year or two, which is a dramatic difference to what it used to be,” Dr Kotschet warned.
The duo reveal a private health system increasingly constrained by outdated policy and structural bottlenecks. For all the talk about value-based care and innovation, the private health system is creeping towards something that looks uncomfortably like US style managed care.
Dr Kotschet reflects on how catheter ablation has advanced in the treatment of atrial fibrillation over the past five years. Yet despite more than half a million Australians living with AF, far fewer than expected receive the procedure due to the imposed ‘cap’.
“I’m left with a less efficient or different procedure to what I would have chosen,” Dr Kotschet said. “For some patients, when you need that [particular] technology for their type of heart disease, you take them publicly.”
If the Productivity Commission acknowledges that healthcare investment delivers a net social benefit, why isn’t that evidence driving faster adoption of innovative health technologies?
“The government’s five pillar productivity agenda calls for a world-class health technology assessment system,” Najdek said. “Quite frankly, we’re still bogged down by outdated processes.”
This conversation is a necessary confrontation with the uncomfortable truth: red tape, policy inertia and misaligned incentives are choking Australians’ expectations of private healthcare and undermining the value of private health insurance.
In reimagining healthcare across the entire patient journey, Health Industry HubTM is the only one-stop-hub uniting the diversity of the Pharma, MedTech, Diagnostics & Biotech sectors to inspire meaningful change.
The Health Industry HubTM content is copyright protected. Access is available under individual user licenses. Please click here to subscribe and visit T&Cs here.
News - Pharmaceuticals
Inside the tensions shaping PBAC decision
The evolving relationship between sponsors, the Pharmaceutical Benefits Advisory Committee (PBAC) and the health technology assessment (HTA) system came under […]
MoreNews - MedTech & Diagnostics
GenesisCare and Omico join forces in precision oncology as Australia sets national genomics agenda
GenesisCare and Omico are teaming up to bring precision oncology to more patients facing incurable, advanced or poor prognosis cancers. […]
MoreNews - MedTech & Diagnostics
MTAA Board election kicks off, setting stage for the next chapter in policy and advocacy
The race for six seats on the Medical Technology Association of Australia (MTAA) Board is underway, with 10 candidates nominated […]
MoreNews - Pharmaceuticals
New breast cancer drug fills gap left by Zoladex market withdrawal
From 1 October 2026, Diphereline (triptorelin 3.75mg) will become available on the Pharmaceutical Benefits Scheme (PBS) for the treatment of […]
More